This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letter to the Editor

Olanzapine for the Treatment of Bipolar Disorder

Saeeduddin Ahmed, MD; Elisabeth K. Degenhardt, RN, MSN; and Hillary C. McGuire, MEd

Published: June 1, 2002

Article Abstract

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: In a recent issue of the Companion, Masand and colleagues1report a retrospective analysis of 36 outpatients withbipolar or schizoaffective disorder in which risperidone and olanzapinewere comparable in efficacy and safety, but treatmentcosts were lower for risperidone-treated patients. Although theacquisition costs of risperidone are lower than those of olanzapine,when other factors are taken into account, the costs of the 2agents do not differ appreciably. As the authors point out in theirarticle, atypical antipsychotics are becoming commonly prescribedagents in primary care settings.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 4

Quick Links: